Effective Strategy for Delivering Nano-Liposomal Encapsulated Mycobacterial ESAT-6 Vaccine Adjuvant in Tuberculosis

Nanoparticles-based biological products need to be explore for finding out newer adjuvants. Most of next generation adjuvants are in clinical trials. Vaccine funding agencies should consider and initiate specific funding programs for adjuvant science and clinical development; even it remains a major roadblock in new vaccine development, too. In current context of research, the authors elaborated the nano-liposomal encapsulated ESAT-6 vaccine subunit adjuvant with chitosan polymers. Methodology involves, for characterization of these, nano-liposomal formulation, particle size, in vitro drug release, and different pre-clinical pharmacology approaches for evaluation of nanovaccine anti-tubercular activity. This research is not exhaustive of all cellular compartments or agents and many subsets have been well reviewed. Indeed, many of these cells or antimicrobial mediators may play significant roles in prevention of Mtb infection, as signs of measurable memory immune responses in some cases are not evident, and could explain why some individuals are resistant to infection.